寛解期の AML 患者における維持療法としての AZA + ベネトクラクス
寛解期の AML 患者における維持療法としての 5-アザシチジン (AZA) + ベネトクラクスの第 II 相試験
This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
調査の概要
状態
介入・治療
詳細な説明
PRIMARY OBJECTIVES:
I. To assess relapse-free survival (RFS) of patients (pts) with acute myeloid leukemia (AML) treated with 5-azacytidine (azacitidine; AZA) combined with venetoclax (VEN) as maintenance therapy after achieving remission.
SECONDARY OBJECTIVES:
I. To assess modified RFS of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
II. To assess overall survival (OS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
III. To assess event-free survival (EFS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
IV. To assess the duration of remission (CRd) of pts with AML treated 5-azacytidine combined with venetoclax as maintenance therapy.
V. To assess toxicity and safety of 5-azacytidine combined with venetoclax as maintenance therapy in pts with AML.
VI. To assess the effects of 5-azacytidine combined with venetoclax on dynamics of minimal residual disease (MRD) and their relationship to outcomes.
OUTLINE:
Patients receive azacitidine subcutaneously (SC) or intravenously (IV) over 1 hour daily on days 1-5, and venetoclax orally (PO) daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 6-12 months thereafter.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- M D Anderson Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients aged >/= 18 years AML who have achieved their FIRST CR or CRi and are not immediately candidates for allogeneic stem cell transplant.
-
Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be enrolled in COHORT 1.
-
Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine (LDAC) or hypomethylating agent (HMA)-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be treated on COHORT 2.
-
For either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement.
-
ECOG performance status of < or = 3
-
Adequate organ function as follows:
- Serum total bilirubin < or = to 1.5 X the Upper Limit of Normal (ULN)
- Serum creatinine < or = to 2.5 x ULN
-
Adequate BM reserve:
- Absolute neutrophil count (ANC) > 0.5 x k/uL
- Platelet count > or = 30 x k/uL
-
For females of childbearing age, they may participate if they:
- Have a negative serum or urine pregnancy test within 10 to 14 days of enrolling
- Agree to either abstinence or 2 effective contraceptive methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment.
-
For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment.
-
Ability to understand and sign informed consent.
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by FAB classification based on morphology, immunophenotype, molecular, or cytogenetic s studies.
- Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor.
- Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with active CNS (central nervous system) disease.
- Patients with documented hypersensitivity to any components of the study program.
- Females who are pregnant or lactating or intending to become pregnant during the study.
- Patients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment.
- Patient should be removed from current trial if they wish to participate and get treatment on another trial.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Treatment (azacytidine, venetoclax)
Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. |
Given PO
他の名前：
Given SC or IV
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Relapse-free survival (RFS)
時間枠：From date of complete remission (CR) or complete remission with incomplete count recovery (CRi), assessed for up to 10 years
|
The study will be continuously monitored for the primary endpoint, RFS, using the method of Thall, Wooten, and Tannir (2005). Will also summarize the posterior distribution of lambda-E (i.e., median RFS) assuming posterior mean and 95% credible interval. |
From date of complete remission (CR) or complete remission with incomplete count recovery (CRi), assessed for up to 10 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of toxicity
時間枠：Up to 10 years
|
Toxicities are defined as any treatment -related clinically significant grade 3 or 4 non-hematologic adverse events occurred during cycles 1-2 of the trial. Will continuously monitor treatment-related toxicities using the Bayesian approach of Thall, Simon, Estey (1995). |
Up to 10 years
|
|
Modified RFS
時間枠：Time from enrollment on study until date of first objective documentation of relapse or death, assessed for up to 10 years
|
Distribution assessed using Kaplan-Meier method. |
Time from enrollment on study until date of first objective documentation of relapse or death, assessed for up to 10 years
|
|
Overall survival (OS)
時間枠：From the start of study treatment until date of death due to any cause, assessed for up to 10 years
|
Distribution assessed using Kaplan-Meier method. |
From the start of study treatment until date of death due to any cause, assessed for up to 10 years
|
|
Event free survival (EFS)
時間枠：From the start of study treatment until date of first confirmed relapse, withdrawal from study due to adverse event, or death due to any cause, assessed for up to 10 years
|
Distribution assessed using Kaplan-Meier method. |
From the start of study treatment until date of first confirmed relapse, withdrawal from study due to adverse event, or death due to any cause, assessed for up to 10 years
|
|
Complete remission duration (CRd)
時間枠：Time from CR or CRi until date of first objective documentation of confirmed relapse, assessed for up to 10 years
|
Distribution assessed using Kaplan-Meier method. |
Time from CR or CRi until date of first objective documentation of confirmed relapse, assessed for up to 10 years
|
協力者と研究者
捜査官
- 主任研究者：Tapan M Kadia、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2019-0226
- 2019-0226 (その他の識別子：M D Anderson Cancer Center)
- NCI-2019-04987 (レジストリ識別子：CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。